|
GSK and Genmab Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin's Lymphoma Genmab A/S / 08.09.2010 23:00 Veröffentlichung einer Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------- ------- Summary: GSK and Genmab announce the initiation of a Phase III study of ofatumumab in rituximab refractory patients with indolent B-cell non-Hodgkin's Lymphoma. London, UK, Copenhagen, Denmark; September 8, 2010 - GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen. Under the terms of Genmab's collaboration with GlaxoSmithKline (GSK), Genmab will receive a milestone payment of approximately DKK 116 million (approximately USD 20 million), triggered by the treatment of the first patient in the study. About the trial A total of 338 patients in this open label study will be randomized to receive either ofatumumab in addition to bendamustine or bendamustine alone. The primary endpoint of the study is progression free survival. Patients in the bendamustine monotherapy group will have the opportunity to receive ofatumumab if their lymphoma progresses. About Indolent B-Cell Non-Hodgkin's Lymphoma More than one-third of lymphoma patients have indolent B-cell non-Hodgkin's lymphoma, which includes follicular lymphoma and other typically slow growing lymphomas which initially respond to treatment but relapse with time.(1) Indolent B-NHL is defined by expression of the CD20 molecule, which is the target of monoclonal antibodies such as rituximab and ofatumumab.(2,3) About ofatumumab Ofatumumab is a human monoclonal antibody which targets CD20. Ofatumumab is not approved in any country for indolent B-cell non-Hodgkin's lymphoma (B-NHL). |
|
| aus der Diskussion: | Glaxosmithkline - Pharma mit Dividende |
| Autor (Datum des Eintrages): | R-BgO (09.09.10 17:54:59) |
| Beitrag: | 4 von 1,036 (ID:40127294) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |